10.48047/jocaaa.2024.32.01.46

ANTIMICROBIOLOGICAL COMPOUNDS – A REVIEW

Dr. Priyambada Singh [1] , Ms. Laiba Arsi [2]
[1] Assistant Professor , Department of Microbiology, Kalinga University , Raipur , CG.
[1] priyambada.singh@kalingauniversity.ac.in
[2] Assistant Professor , Department of Microbiology, Kalinga University , Raipur , CG.
[2] laiba.arshi@kalingauniversity.ac.in
Correspondence author- priyambada.singh@kalingauniversity.ac.in

Abstract Antimicrobiological compounds represent one of the greatest scientific breakthroughs in modern medicine and biotechnology, with profound applications across healthcare, veterinary practice, agriculture, and industry. These compounds include antibiotics, antifungals, antivirals, and antiparasitics, derived from natural, semi-synthetic, and synthetic sources. Their discovery, beginning with penicillin in 1928, revolutionized clinical medicine by drastically reducing mortality from infectious diseases and enabling complex surgical procedures, organ transplantation, and cancer therapy. This review categorizes antimicrobiological compounds based on their origin, target microorganisms, and mechanisms of action, ranging from inhibition of cell wall biosynthesis and protein synthesis to disruption of nucleic acids, membranes, and metabolic pathways. Sources include plants, microbial metabolites, marine organisms, and synthetic molecules, with emerging contributions from nanotechnology and synthetic biology.

Despite their indispensable role, antimicrobials face a global crisis due to antimicrobial resistance (AMR), fueled by misuse in human health, veterinary practice, and agriculture. Mechanisms such as enzymatic degradation, efflux pumps, target modification, and biofilm formation have led to the emergence of multidrug-resistant pathogens. AMR poses a significant threat to global health, food security, and economic development, with projections of 10 million deaths annually by 2050 if left unchecked. To address these challenges, strategies such as antimicrobial stewardship, combination therapies, novel drug discovery, and adoption of the **One Health approach** are essential. Emerging alternatives, including phytochemicals, probiotics, bacteriophage therapy, CRISPR-Cas systems, and nanotechnology-based antimicrobials, offer promising prospects for sustainable antimicrobial development.

This review underscores the critical importance of responsible antimicrobial use, interdisciplinary research, and international collaboration. By integrating advances in natural product discovery, nanotechnology, and synthetic biology, alongside robust global policy

10.48047/jocaaa.2024.32.01.46

frameworks, the future of antimicrobiological compounds can be safeguarded to preserve their effectiveness for generations to come.

Keywords Antimicrobiological compounds; Antibiotics; Antifungals; Antivirals; Antiparasitics; Antimicrobial resistance (AMR); Natural products; Nanotechnology; Phytochemicals; Bacteriophage therapy; CRISPR-Cas; One Health

1. Introduction

Definition of Antimicrobiological Compounds Antimicrobiological compounds, often referred to as **antimicrobials**, are substances that either kill or inhibit the growth of microorganisms such as bacteria, fungi, viruses, and parasites. These include a wide range of **antibiotics, antifungals, antivirals, and antiparasitic agents**, derived from natural, semi-synthetic, or synthetic sources (Davies & Davies, 2010). They are indispensable in both clinical and non-clinical contexts, forming the cornerstone of infectious disease management.

Historical Background of Antimicrobial Discovery The history of antimicrobials can be traced back to the use of natural products such as honey, plant extracts, and fermented materials in traditional medicine. However, the modern era began with the discovery of **penicillin by Alexander Fleming in 1928**, which marked the start of the "golden age" of antibiotics (Fleming, 1929; Ligon, 2004). This discovery was followed by the isolation of **streptomycin, tetracyclines, and macrolides** during the mid-20th century, largely from actinomycetes and fungi (Lewis, 2013). The subsequent development of synthetic and semi-synthetic derivatives, including sulfonamides and fluoroquinolones, greatly expanded the antimicrobial arsenal (Wright, 2012). These discoveries revolutionized medicine, drastically reducing mortality from previously lethal infections and enabling advances in surgery, transplantation, and cancer chemotherapy.

Table 1.1: Historical Timeline of Antimicrobial Discovery (1928–Present)

Year	Compound/Drug Class	Source/Developer	Significance

10.48047/jocaaa.2024.32.01.46

Year	**Compound/Drug Class**	**Source/Developer**	**Significance**
1928	Penicillin	*Penicillium notatum* (Alexander Fleming)	First true antibiotic; revolutionized treatment of bacterial infections.
1935	Sulfonamides (Prontosil)	Synthetic (Gerhard Domagk)	First synthetic antimicrobial drug; effective against streptococcal infections.
1943	Streptomycin	*Streptomyces griseus* (Selman Waksman)	First antibiotic effective against tuberculosis.
1948	Chloramphenicol	*Streptomyces venezuelae*	First broad-spectrum antibiotic used widely in clinical practice.
1950s	Tetracyclines	*Streptomyces aureofaciens*	Broad-spectrum antibiotic; effective in respiratory and urinary infections.
1952	Erythromycin (Macrolides)	*Saccharopolyspora erythraea*	Alternative for penicillin-allergic patients.
1953	Vancomycin (Glycopeptide)	*Amycolatopsis orientalis*	Effective against Gram-positive infections, including MRSA.
1962	Nalidixic acid (Quinolones)	Synthetic	First quinolone; precursor to fluoroquinolones.
1967	Rifamycins (Rifampicin)	*Amycolatopsis rifamycinica*	Key drug against tuberculosis and leprosy.
1976	Carbapenems (Imipenem)	Synthetic derivative of thienamycin	Broad-spectrum β-lactam antibiotic with high stability against β-lactamases.
1981	Acyclovir (Antiviral)	Synthetic guanosine analogue	First major antiviral; effective against herpes viruses.
1987	Fluoroquinolones	Synthetic	Highly effective broad-spectrum

10.48047/jocaaa.2024.32.01.46

Year	Compound/Drug Class	Source/Developer	Significance
	(Ciprofloxacin)		antibiotics for respiratory and urinary tract infections.
1990s	Azoles (Fluconazole)	Synthetic	Systemic antifungal agent; safer profile for long-term use.
2000	Linezolid (Oxazolidinones)	Synthetic	First new antibiotic class in decades; active against resistant Gram-positives.
2001	Daptomycin (Lipopeptide)	*Streptomyces roseosporus*	Effective against MRSA and VRE (vancomycin-resistant enterococci).
2015	Teixobactin	*Eleftheria terrae* (uncultured soil bacterium)	Novel mechanism; no resistance observed in initial studies.
2017–Present	CRISPR-Cas antimicrobials & Nanoparticles	Engineered/Synthetic	New-generation alternatives targeting resistance genes and biofilms.

Importance in Human Health, Agriculture, Veterinary Medicine, and Industry
In **human health**, antimicrobials remain critical for controlling infectious diseases such as pneumonia, tuberculosis, and HIV/AIDS, saving millions of lives annually (Ventola, 2015). In **veterinary medicine**, they are employed to treat livestock and companion animals, thereby maintaining animal health and welfare. In **agriculture**, antimicrobials are used to protect crops from fungal and bacterial pathogens, ensuring food security (McManus et al., 2002). Beyond healthcare and agriculture, they play vital roles in **industrial applications** such as food preservation, biocides in water treatment, and sterilization of medical equipment (Kümmerer, 2009).

Challenges: Antimicrobial Resistance, Side Effects, and Environmental Impacts
Despite their benefits, antimicrobial use is not without challenges. One of the most pressing

10.48047/jocaaa.2024.32.01.46

concerns is **antimicrobial resistance (AMR)**, wherein microorganisms develop mechanisms to evade drug action, rendering treatments ineffective (WHO, 2020). Overuse and misuse of antimicrobials in healthcare, livestock, and agriculture have accelerated the rise of resistant strains, including multidrug-resistant *Mycobacterium tuberculosis* and methicillin-resistant *Staphylococcus aureus* (MRSA) (Laxminarayan et al., 2013). Additionally, antimicrobials can cause adverse effects ranging from gastrointestinal disturbances to severe allergic reactions. Their widespread use has also led to **environmental contamination**, with residues detected in soil and water ecosystems, contributing to ecological imbalance and resistance gene dissemination (Kümmerer, 2009).

Aim and Scope of the Review Given these challenges, this review aims to provide a comprehensive examination of **antimicrobiological compounds**, covering their classification, sources, mechanisms of action, applications, and the growing problem of resistance. Special emphasis will be placed on recent advances in antimicrobial discovery, including natural products, nanotechnology-based antimicrobials, and alternative strategies such as probiotics and phage therapy. The scope extends beyond clinical applications to include agricultural, veterinary, and industrial contexts, highlighting the need for a **holistic, One Health approach** to sustainable antimicrobial use (Robinson et al., 2016).

10.48047/jocaaa.2024.32.01.46



Figure 1.2: Global Importance of Antimicrobiological Compounds in Human, Veterinary, Agricultural, and Industrial Sectors

2. Classification of Antimicrobiological Compounds

The classification of antimicrobiological compounds is essential for understanding their diversity, mechanisms, and applications. These compounds can be categorized based on **origin**, **target microorganism**, and **mode of action**.

2.1 Based on Origin

- **Natural Compounds:** Derived from microorganisms (e.g., *Penicillium* producing penicillin, *Streptomyces* producing streptomycin), plants (alkaloids, flavonoids), and marine organisms (sponges, algae). These sources have historically provided most antibiotic scaffolds (Newman & Cragg, 2016).
- **Semi-synthetic Compounds:** Modified versions of natural products to improve stability, activity, or spectrum, e.g., amoxicillin and erythromycin derivatives (Walsh & Wencewicz, 2014).

10.48047/jocaaa.2024.32.01.46

- **Synthetic Compounds:** Designed entirely in laboratories, such as sulfonamides and fluoroquinolones, which revolutionized antimicrobial therapy in the 20th century (Wright, 2012).

2.2 Based on Target Microorganism

- **Antibacterial:** β-lactams, tetracyclines, aminoglycosides, macrolides.
- **Antifungal:** Polyenes (amphotericin B), azoles (fluconazole), echinocandins (caspofungin).
- **Antiviral:** Nucleoside analogues (acyclovir), protease inhibitors, reverse transcriptase inhibitors.
- **Antiparasitic:** Artemisinin, chloroquine, ivermectin.

2.3 Based on Mode of Action

- **Cell wall synthesis inhibitors:** β-lactams (penicillin, cephalosporins), glycopeptides (vancomycin).
- **Protein synthesis inhibitors:** Tetracyclines, macrolides, aminoglycosides (Kohanski et al., 2010).
- **Nucleic acid synthesis inhibitors:** Fluoroquinolones, rifamycins.
- **Membrane disruptors:** Polymyxins, daptomycin.
- **Metabolic pathway inhibitors:** Sulfonamides (folate pathway inhibitors).

3. Sources of Antimicrobiological Compounds

Antimicrobial agents originate from diverse natural and synthetic sources.

3.1 Plant-Derived Compounds

Plants produce **secondary metabolites** such as **alkaloids, flavonoids, terpenoids, and tannins** with antimicrobial properties (Cowan, 1999). Essential oils (e.g., thymol, eugenol) have shown broad-spectrum antimicrobial activity (Burt, 2004). Phytochemicals are increasingly explored due to their reduced resistance potential and biocompatibility.

3.2 Microbial-Derived Compounds

Microbes, particularly **actinomycetes** and fungi, remain the richest source of antibiotics. Examples include **streptomycin from *Streptomyces griseus*** and **penicillin from *Penicillium chrysogenum*** (Demain & Sanchez, 2009). These discoveries shaped the antibiotic industry, with

10.48047/jocaaa.2024.32.01.46

Streptomyces alone contributing over two-thirds of clinically useful antibiotics (Barka et al., 2016).

3.3 Marine Organisms

Marine ecosystems are a frontier in antimicrobial discovery. Sponges, algae, and mollusks produce unique bioactive compounds such as **bromophenols and marine peptides** (Mayer et al., 2010). These are structurally distinct from terrestrial molecules, providing novel drug scaffolds.

3.4 Synthetic and Nanotechnology-Based Compounds

The advancement of **synthetic chemistry** and **nanotechnology** has introduced engineered antimicrobials. **Silver nanoparticles (AgNPs)** and **zinc oxide nanoparticles** exhibit potent antimicrobial activity via reactive oxygen species generation and membrane disruption (Rai et al., 2012). Synthetic derivatives such as **fluoroquinolones** demonstrate broad-spectrum activity with high efficacy.

Summary: The sources of antimicrobiological compounds are diverse, ranging from natural ecosystems to advanced nanotechnology, ensuring a continuous pipeline for novel drug discovery.

4. Mechanisms of Action

Understanding how antimicrobiological compounds work is crucial for effective therapeutic application and combating resistance.

4.1 Inhibition of Cell Wall Biosynthesis

Bacteria rely on peptidoglycan for structural integrity. Compounds such as **β-lactams (penicillin, cephalosporins)** inhibit **penicillin-binding proteins**, disrupting cell wall synthesis and leading to lysis (Tipper & Strominger, 1965). **Glycopeptides (vancomycin)** bind to D-Ala-D-Ala termini, preventing cross-linking.

4.2 Inhibition of Protein Synthesis

Ribosomes are primary targets:

- **Aminoglycosides** bind to the 30S ribosomal subunit, causing misreading of mRNA.
- **Tetracyclines** block tRNA binding to the ribosome.
- **Macrolides** bind to the 50S subunit, preventing translocation (Wilson, 2014).

4.3 Disruption of Membrane Integrity

10.48047/jocaaa.2024.32.01.46

Polymyxins interact with lipopolysaccharides of Gram-negative bacteria, compromising membrane integrity. **Daptomycin** inserts into Gram-positive membranes, causing depolarization (Falagas & Kasiakou, 2005).

4.4 Inhibition of Nucleic Acid Synthesis

- **Fluoroquinolones** inhibit DNA gyrase and topoisomerase IV.
- **Rifamycins** bind to RNA polymerase, blocking transcription (Hooper, 2001).

4.5 Metabolic Pathway Inhibition

Sulfonamides and **trimethoprim** target folate biosynthesis, crucial for nucleotide production. Their combination (co-trimoxazole) provides synergistic activity (Huovinen et al., 1995).

4.6 Novel Mechanisms

Emerging antimicrobials include **antimicrobial peptides** disrupting multiple targets and **CRISPR-based gene editing systems** targeting resistance genes (Bikard & Barrangou, 2017).

5. Applications of Antimicrobiological Compounds

Antimicrobiological compounds are indispensable across multiple domains, ranging from clinical medicine to agriculture, veterinary practice, and industrial use.

5.1 Medical Applications

In human health, antimicrobials are the primary defense against infectious diseases. **Antibiotics** treat bacterial infections such as pneumonia, tuberculosis, and meningitis, significantly reducing mortality rates (Ventola, 2015). **Antifungal agents** like amphotericin B and fluconazole are critical for systemic mycoses in immunocompromised patients, such as those with HIV/AIDS (Perfect, 2017). **Antivirals**, including acyclovir and antiretroviral therapies, have transformed HIV and herpesvirus treatment, while direct-acting antivirals (DAAs) have revolutionized hepatitis C therapy (Pawlotsky, 2014). Furthermore, antimicrobials play vital prophylactic roles in surgical procedures, organ transplantation, and cancer chemotherapy, where infection risk is heightened (Surgical Infection Society, 2017).

5.2 Veterinary Applications

In veterinary medicine, antimicrobials safeguard livestock and companion animals. Drugs such as tetracyclines, macrolides, and sulfonamides are used to treat respiratory, enteric, and systemic infections (Aidara-Kane et al., 2018). Beyond therapeutic use, antimicrobials have been employed as **growth promoters in animal husbandry**, though this practice is increasingly restricted due to resistance concerns.

5.3 Agricultural Applications

Antimicrobials are extensively used to manage crop diseases caused by fungi and bacteria. **Streptomycin** and **oxytetracycline** are applied in orchards to control fire blight and bacterial spot (McManus et al., 2002). Fungicides like azoles are employed against rusts and blights. These interventions secure yields and global food supplies, although the overuse of antibiotics in agriculture is a growing concern.

5.4 Industrial Applications

Antimicrobials are used in **food preservation**, water treatment, and the production of sterile products. Compounds such as nisin, a bacteriocin, are approved as food preservatives due to their ability to inhibit Gram-positive bacteria (Delves-Broughton et al., 1996). Antimicrobials are also incorporated into coatings for medical devices and hospital surfaces to reduce infection risk (Cloutier et al., 2015).

6. Antimicrobial Resistance (AMR)

6.1 Global Threat

The emergence of **antimicrobial resistance (AMR)** is one of the greatest public health threats of the 21st century. The WHO (2020) warns that without effective antimicrobials, common infections and minor surgeries could become life-threatening.

6.2 Mechanisms of Resistance

- **Enzymatic degradation:** β-lactamases hydrolyze penicillins and cephalosporins (Bush & Bradford, 2016).
- **Target modification:** MRSA modifies penicillin-binding proteins, reducing β-lactam binding (Chambers & DeLeo, 2009).
- **Efflux pumps:** Found in Gram-negative bacteria, these remove drug molecules (Li et al., 2015).
- **Biofilm formation:** Protective communities increase tolerance to antimicrobials.

6.3 Drivers of AMR

10.48047/jocaaa.2024.32.01.46

Overuse and misuse of antibiotics in healthcare, agriculture, and veterinary practice are primary drivers. Lack of adherence to treatment regimens, availability of over-the-counter antibiotics, and poor infection control further exacerbate resistance (Laxminarayan et al., 2013).

6.4 Global Health Impact

By 2050, AMR could cause 10 million deaths annually if unchecked, surpassing cancer mortality (O'Neill, 2016). Resistant pathogens such as carbapenem-resistant *Enterobacteriaceae* and vancomycin-resistant *Enterococcus* are already causing untreatable infections.

6.5 Strategies to Combat AMR

- **Antibiotic stewardship programs** to regulate prescribing.
- **Combination therapies** (e.g., β-lactam with β-lactamase inhibitors).
- **Novel drug discovery** targeting new pathways.
- **Alternatives:** probiotics, bacteriophage therapy, CRISPR-based antimicrobials (Bikard & Barrangou, 2017).
- **Global cooperation:** WHO's *Global Action Plan on AMR* emphasizes a **One Health** approach (Robinson et al., 2016).

7. Emerging Trends and Future Prospects

7.1 Phytochemicals and Natural Products

Plant-derived antimicrobials are being rediscovered due to their broad activity and reduced resistance potential. Essential oils, alkaloids, and flavonoids are being tested as food preservatives and alternative therapies (Cowan, 1999).

7.2 Nanotechnology-Based Antimicrobials

Nanoparticles (AgNPs, ZnO-NPs, TiO_2-NPs) display strong antimicrobial effects by disrupting membranes and producing reactive oxygen species (Rai et al., 2012). Nano-formulations also enhance drug delivery, solubility, and bioavailability.

7.3 Probiotics and Postbiotics

Beneficial microbes and their metabolic products are being explored as alternatives to antibiotics, especially in gut health and animal husbandry (Ouwehand et al., 2002).

7.4 Bacteriophage Therapy

Phages, viruses that infect bacteria, are re-emerging as precision tools against resistant bacteria. Clinical trials are underway, with promising results in multidrug-resistant infections (Lin et al., 2017).

7.5 CRISPR-Cas and Gene Editing Approaches

CRISPR-Cas systems are being engineered to target resistance genes, enabling selective killing of resistant bacteria (Bikard & Barrangou, 2017).

7.6 Synthetic Biology

Advances in synthetic biology are allowing the design of **new antimicrobial peptides and synthetic pathways** for novel drugs (Walsh & Wencewicz, 2014).

7.7 One Health Approach

The **One Health paradigm** integrates human, animal, and environmental health perspectives, recognizing that AMR must be addressed across all ecosystems (Robinson et al., 2016).

8. Conclusion

Antimicrobiological compounds remain among the greatest achievements of modern science. They have saved countless lives, enabled advanced medicine, and secured agricultural productivity. However, the **widespread emergence of resistance** threatens to undermine these gains. The challenge is not only scientific but also social, economic, and political.

This review highlights the **classification, sources, mechanisms, applications, and challenges** associated with antimicrobials. The growing crisis of AMR underscores the need for **responsible stewardship, innovative research, and global collaboration**. Future directions point toward **phytochemicals, nanotechnology, probiotics, bacteriophages, and CRISPR-based therapies**, which may offer alternatives or complements to conventional drugs.

Ultimately, the sustainability of antimicrobiological compounds depends on embracing **interdisciplinary strategies** and a **One Health framework**, ensuring these life-saving agents remain effective for generations to come.

References

- Aidara-Kane, A., Angulo, F. J., Conly, J. M., Minato, Y., Silbergeld, E. K., McEwen, S. A., ... & Collignon, P. J. (2018). World Health Organization (WHO) guidelines on use of

10.48047/jocaaa.2024.32.01.46

medically important antimicrobials in food-producing animals. *Antimicrobial Resistance & Infection Control*, 7(1), 7.

- Barka, E. A., Vatsa, P., Sanchez, L., Gavaut-Vaillant, N., Jacquard, C., Meier-Kolthoff, J. P. & Clément, C. (2016). Taxonomy, physiology, and natural products of *Streptomyces*. *Microbiology and Molecular Biology Reviews*, 80(1), 1–43.
- Bikard, D., & Barrangou, R. (2017). Using CRISPR-Cas systems as antimicrobials. *Current Opinion in Microbiology*, 37, 155–160.
- Bikard, D., & Barrangou, R. (2017). Using CRISPR-Cas systems as antimicrobials. *Current Opinion in Microbiology*, 37, 155–160.
- Burt, S. (2004). Essential oils: their antibacterial properties and potential applications in foods. *International Journal of Food Microbiology*, 94(3), 223–253.
- Bush, K., & Bradford, P. A. (2016). β-Lactams and β-lactamase inhibitors: an overview. *Cold Spring Harbor Perspectives in Medicine*, 6(8), a025247.
- Chambers, H. F., & DeLeo, F. R. (2009). Waves of resistance: Staphylococcus aureus in the antibiotic era. *Nature Reviews Microbiology*, 7(9), 629–641.
- Cloutier, M., Mantovani, D., & Rosei, F. (2015). Antibacterial coatings: Challenges, perspectives, and opportunities. *Trends in Biotechnology*, 33(11), 637–652.
- Cowan, M. M. (1999). Plant products as antimicrobial agents. *Clinical Microbiology Reviews*, 12(4), 564–582.
- Davies, J., & Davies, D. (2010). Origins and evolution of antibiotic resistance. *Microbiology and Molecular Biology Reviews*, 74(3), 417–433.
- Delves-Broughton, J., Blackburn, P., Evans, R. J., & Hugenholtz, J. (1996). Applications of the bacteriocin, nisin. *Antonie van Leeuwenhoek*, 69(2), 193–202.
- Demain, A. L., & Sanchez, S. (2009). Microbial drug discovery: 80 years of progress. *The Journal of Antibiotics*, 62(1), 5–16.
- Falagas, M. E., & Kasiakou, S. K. (2005). Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. *Clinical Infectious Diseases*, 40(9), 1333–1341.
- Fleming, A. (1929). On the antibacterial action of cultures of a *Penicillium*, with special reference to their use in the isolation of *B. influenzae*. *British Journal of Experimental Pathology*, 10(3), 226–236.

- Hooper, D. C. (2001). Mechanisms of action and resistance of older and newer fluoroquinolones. *Clinical Infectious Diseases*, 31(Suppl 2), S24–S28.
- Huovinen, P., Sundström, L., Swedberg, G., & Sköld, O. (1995). Trimethoprim and sulfonamide resistance. *Antimicrobial Agents and Chemotherapy*, 39(2), 279–289.
- Kohanski, M. A., Dwyer, D. J., & Collins, J. J. (2010). How antibiotics kill bacteria: from targets to networks. *Nature Reviews Microbiology*, 8(6), 423–435.
- Kümmerer, K. (2009). Antibiotics in the aquatic environment–A review–Part I. *Chemosphere*, 75(4), 417–434.
- Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K., Wertheim, H. F., Sumpradit, N., ... & Cars, O. (2013). Antibiotic resistance—the need for global solutions. *The Lancet Infectious Diseases*, 13(12), 1057–1098.
- Lewis, K. (2013). Platforms for antibiotic discovery. *Nature Reviews Drug Discovery*, 12(5), 371–387.
- Li, X. Z., Plésiat, P., & Nikaido, H. (2015). The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. *Clinical Microbiology Reviews*, 28(2), 337–418.
- Ligon, B. L. (2004). Penicillin: its discovery and early development. *Seminars in Pediatric Infectious Diseases*, 15(1), 52–57.
- Lin, D. M., Koskella, B., & Lin, H. C. (2017). Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. *World Journal of Gastrointestinal Pharmacology and Therapeutics*, 8(3), 162.
- Mayer, A. M., Rodríguez, A. D., Taglialatela-Scafati, O., & Fusetani, N. (2010). Marine pharmacology in 2007–8. *Marine Drugs*, 8(12), 2619–2694.
- Mayer, A. M., Rodríguez, A. D., Taglialatela-Scafati, O., & Fusetani, N. (2010). Marine pharmacology in 2007–8: marine compounds with antibacterial, antidiabetic, antifungal, anti-inflammatory, and antiviral activities. *Marine Drugs*, 8(12), 2619–2694.
- McManus, P. S., Stockwell, V. O., Sundin, G. W., & Jones, A. L. (2002). Antibiotic use in plant agriculture. *Annual Review of Phytopathology*, 40(1), 443–465.
- Newman, D. J., & Cragg, G. M. (2016). Natural products as sources of new drugs from 1981 to 2014. *Journal of Natural Products*, 79(3), 629–661.
- O'Neill, J. (2016). Tackling drug-resistant infections globally: Final report and recommendations. *The Review on Antimicrobial Resistance*.

- Ouwehand, A. C., Salminen, S., & Isolauri, E. (2002). Probiotics: an overview of beneficial effects. *Antonie van Leeuwenhoek*, 82(1–4), 279–289.
- Pawlotsky, J. M. (2014). New hepatitis C therapies: The toolbox, strategies, and challenges. *Gastroenterology*, 146(5), 1176–1192.
- Perfect, J. R. (2017). The antifungal pipeline: A reality check. *Nature Reviews Drug Discovery*, 16(9), 603–616.
- Rai, M., Yadav, A., & Gade, A. (2012). Silver nanoparticles as a new generation of antimicrobials. *Biotechnology Advances*, 27(1), 76–83.

- Rai, M., Yadav, A., & Gade, A. (2012). Silver nanoparticles as a new generation of antimicrobials. *Biotechnology Advances*, 27(1), 76–83.

- Robinson, T. P., Bu, D. P., Carrique-Mas, J., Fèvre, E. M., Gilbert, M., Grace, D., ... & Woolhouse, M. E. (2016). Antibiotic resistance is the quintessential One Health issue. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 110(7), 377–380.

- Robinson, T. P., Bu, D. P., Carrique-Mas, J., Fèvre, E. M., Gilbert, M., Grace, D., ... & Woolhouse, M. E. (2016). Antibiotic resistance is the quintessential One Health issue. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 110(7), 377–380.

- Surgical Infection Society. (2017). Antimicrobial prophylaxis for surgery: guidelines. *Surgical Infections*, 18(4), 383–400.
- Tipper, D. J., & Strominger, J. L. (1965). Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-D-alanyl-D-alanine. *Proceedings of the National Academy of Sciences*, 54(4), 1133–1141.
- Ventola, C. L. (2015). The antibiotic resistance crisis: Part 1: Causes and threats. *P&T*, 40(4), 277–283.

- Ventola, C. L. (2015). The antibiotic resistance crisis: Part 1: Causes and threats. *P&T*, 40(4), 277–283.

- Walsh, C. T., & Wencewicz, T. A. (2014). Prospects for new antibiotics: a molecule-centered perspective. *The Journal of Antibiotics*, 67(1), 7–22.

- Walsh, C. T., & Wencewicz, T. A. (2014). Prospects for new antibiotics: a molecule-centered perspective. *The Journal of Antibiotics*, 67(1), 7–22.

- Wilson, D. N. (2014). Ribosome-targeting antibiotics and mechanisms of bacterial resistance. *Nature Reviews Microbiology*, 12(1), 35–48.

10.48047/jocaaa.2024.32.01.46

- World Health Organization. (2020). Antimicrobial resistance. Retrieved from https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
- Wright, G. D. (2012). Antibiotics: a new hope. *Chemistry & Biology*, 19(1), 3–10.